Aerosol therapy for malignancy involving the lungs

Current Cancer Drug Targets

Volumn 3, Issue 4, 2003, Pages 239-250

  Rao, R D ^a   Markovic, S N ^a   Anderson, P M ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DACARBAZINE; DIMYRISTOYLPHOSPHATIDYLCHOLINE; DOXORUBICIN; FLUOROURACIL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; HUMAN SERUM ALBUMIN; INTERLEUKIN 2 RECEPTOR; ISOTRETINOIN; RECOMBINANT ALPHA INTERFERON; RECOMBINANT GAMMA INTERFERON; RECOMBINANT INTERLEUKIN 2;

AEROSOL; ANASARCA; ANEMIA; ANOREXIA; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER REGRESSION; CANCER SURVIVAL; CAPILLARY LEAK SYNDROME; CHEMOPROPHYLAXIS; CHILL; CLINICAL TRIAL; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG ELIMINATION; DRUG FEVER; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; GENE THERAPY; HUMAN; IMMUNOMODULATION; KIDNEY CARCINOMA; KIDNEY DISEASE; LIVER DYSFUNCTION; LUNG CANCER; LUNG EDEMA; LUNG METASTASIS; LYMPHOKINE ACTIVATED KILLER CELL; MALAISE; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; META ANALYSIS; NAUSEA; NEBULIZATION; NONHUMAN; OUTCOMES RESEARCH; OVARY CARCINOMA; POWDER; RECEPTOR UPREGULATION; REVIEW; THROMBOCYTOPENIA;

ADMINISTRATION, INHALATION; AEROSOLS; ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; CYTOKINES; HUMANS; LUNG NEOPLASMS;

EID: 0042129894     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568009033481895     Document Type: Review

References (63)

1. Fidler, I. J.; Gersten, D. M.; Hart, I. R. The Biology of Cancer Invasion and Metastasis. Adv. Cancer Res. 1978, 28, 149-250.
2. Sone, S. Role of Alveolar Macrophages in Pulmonary Neoplasias. Biochim. Biophys. Acta 1986, 823, 227-45.
3. Fidler, I. J.; Schroit, A. J. Synergism Between Lymphokines and Muramyl Dipeptide Encapsulated in Liposomes: in Situ Activation of Macrophages and Therapy of Spontaneous Cancer Metastases. J. Immunol. 1984, 133, 515-518.
4. Giosue, S.; Casarini, M.; Ameglio, F.; Zangrilli, P.; Palla, M.; Altieri, A.M.; Bisetti, A. Aerosolized Interferon-Alpha Treatment in Patients with Multi-Drug-Resistant Pulmonary Tuberculosis. Eur. Cytokine Netw. 2000, 11, 99-104.
5. Marshall, M. V.; Mclemore, T. L.; Martin, R. R.; Jenkins, W. T.; Snodgrass, D. R.; Corson, M. A.; Arnott, M. S.; Wray, N. P.; Griffin, A. C. Patterns of Benzo[Alpha]Pyrene Metabolism in Normal Human Pulmonary Alveolar Macrophages. Cancer Lett. 1979, 8, 103-109.
6. Rosenberg, S. A.; Spiess, P.; Lafreniere, R. A New Approach to the Adoptive Immunotherapy of Cancer with Tumor-Infiltrating Lymphocytes. Science 1986, 233, 1318-1321.
7. Sone, S.; Key, M. E. Antitumor and Phagocytic Activities of Rat Alveolar Macrophage Subpopulations Separated on a Discontinuous Gradient of Bovine Serum Albumin. J. Biol. Response Mod. 1986, 5, 595-603.
8. Zissel, G.; Aulitzky, W. E.; Lorenz, J.; Huber, C.; Muller-Quernheim, J. Induction of Accessory Cell Function of Human Alveolar Macrophages by Inhalation of Human Natural Interleukin-2. Cancer Immunol. Immunother. 1996, 42, 122-126.
9. Shiloni, E.; Lafreniere, R.; Mule, J. J.; Schwarz, S. L.; Rosenberg, S. A. Effect of Immunotherapy with Allogeneic Lymphokine-Activated Killer Cells and Recombinant Interleukin 2 on Established Pulmonary and Hepatic Metastases in Mice. Cancer Res. 1986, 46, 5633-5640.
10. Anderson, P. M.; Sorenson, M. A. Effects of Route and Formulation on Clinical Pharmacokinetics of Interleukin-2. Clin. Pharmacokinet. 1994, 27, 19-31.
11. Anderson, P. M.; Markovic, S. N.; Sloan, J. A.; Clawson, M. L.; Wylam, M.; Arndt, C. A.; Smithson, W. A.; Burch, P.; Gormet, M.; Rahman, E. Aerosol Granulocyte Macrophage-Colony Stimulating Factor: A Low Toxicity, Lung-Specific Biological Therapy in Patients with Lung Metastases. Clin. Cancer Res. 1999, 5, 2316-2323.
12. Khanna, C.; Hasz, D. E.; Klausner, J. S.; Anderson, P. M. Aerosol Delivery of Interleukin 2 Liposomes Is Nontoxic and Biologically Effective: Canine Studies. Clin. Cancer Res. 1996, 2, 721-734.
13. Khanna, C.; Waldrep, J. C.; Anderson, P. M.; Weischelbaum, R. W.; Hasz, D. E.; Katsanis, E.; Klausner, J. S. Nebulized Interleukin 2 Liposomes: Aerosol Characteristics and Biodistribution. J. Pharm. Pharmacol. 1997, 49, 960-971.
14. Khanna, C.; Anderson, P. M.; Hasz, D. E.; Katsanis, E.; Neville, M.; Klausner, J. S. Interleukin-2 Liposome Inhalation Therapy Is Safe and Effective For Dogs with Spontaneous Pulmonary Metastases. Cancer 1997, 79, 1409-1421.
15. Knight, V.; Koshkina, N.; Waldrep, C.; Giovanella, B. C.; Kleinerman, E.; Gilbert, B. Anti-Cancer Activity of 9-Nitrocamptothecin Liposome Aerosol in Mice. Trans. Am. Clin. Climatol. Assoc. 2000, 111, 135-145.
16. Skubitz, K. M.; Anderson, P. M. Inhalational Interleukin-2 Liposomes For Pulmonary Metastases: A Phase I Clinical Trial. Anticancer Drugs 2000, 11, 555-563.
17. Rosenberg, S. A.; Lotze, M. T.; Muul, L. M.; Chang, A. E.; Avis, F. P.; Leitman, S.; Linehan, W. M.; Robertson, C. N.; Lee, R. E.; Rubin, J. T. et al. A Progress Report on The Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone. N. Engl. J. Med. 1987, 316, 889-897.
18. Huland, E.; Heinzer, H.; Huland, H.; Yung, R. Overview of Interleukin-2 Inhalation Therapy. Cancer J. Sci. Am. 2000, 6 Suppl 1, S104-S112.
19. Anderson, P. M.; Katsanis, E.; Leonard, A. S.; Schow, D.; Loeffler, C. M.; Goldstein, M. B.; Ochoa, A. C. Increased Local Antitumor Effects of Interleukin 2 Liposomes in Mice with MCA-106 Sarcoma Pulmonary Metastases. Cancer Res. 1990, 50, 1853-1856.
20. West, W. H.; Tauer, K. W.; Yannelli, J. R.; Marshall, G. D.; Orr, D. W.; Thurman, G. B.; Oldham, R. K. Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced Cancer. N. Engl. J. Med. 1987, 316, 898-905.
21. Negrier, S.; Philip, T.; Stoter, G.; Fossa, S. D.; Janssen, S.; Iacone, A.; Cleton, F. S.; Eremin, O.; Israel, L.; Jasmin, C. and Et Al. Interleukin-2 with Or without LAK Cells in Metastatic Renal Cell Carcinoma: A Report of A European Multicentre Study. Eur J. Cancer Clin. Oncol. 1989, 25, S21-S28.
22. Huland, E.; Huland, H.; Heinzer, H. Interleukin-2 by Inhalation: Local Therapy for Metastatic Renal Cell Carcinoma. J. Urol. 1992, 147, 344-348.
23. Elson, P. J.; Witte, R. S.; Trump, D. L. Prognostic Factors For Survival in Patients with Recurrent or Metastatic Renal Cell Carcinoma. Cancer Res. 1988, 48, 7310-7313.
24. Huland, E.; Heinzer, H.; Huland, H. Inhaled Interleukin-2 in Combination with Low-Dose Systemic Interleukin-2 and Interferon Alpha in Patients with Pulmonary Metastatic Renal-Cell Carcinoma: Effectiveness and Toxicity of Mainly Local Treatment. J. Cancer Res. Clin. Oncol 1994, 120, 221-228.
25. Lorenz, J.; Wilhelm, K.; Kessler, M.; Peschel, C.; Schwulera, U.; Lissner, R.; Struff, W. G.; Huland, E.; Huber, C.; Aulitzky, W. E. Phase I Trial of Inhaled Natural Interleukin 2 for Treatment of Pulmonary Malignancy: Toxicity, Pharmacokinetics, and Biological Effects. Clin. Cancer Res. 1996, 2, 1115-1122.
26. Bocci, V. Evaluation of Routes of Administration of Interferon in Cancer: A Review and A Proposal. Cancer Drug Deliv. 1984, 1, 337-351.
27. Eisenberg, B. L.; Taylor, D. D.; Weese, J. L. Aerosolized Gamma-Interferon and Lipopolysaccharide Enhances Cytotoxicity of Murine Pulmonary Alveolar Macrophages. J. Immunother. 1991, 10, 51-56.
28. Wyde, P. R.; Wilson, S. Z.; Kramer, M. J.; Sun, C. S.; Knight, V. Pulmonary Deposition and Clearance of Aerosolized Interferon. Antimicrob. Agents Chemother. 1984, 25, 729-734.
29. Lack, G.; Renz, H.; Saloga, J.; Bradley, K. L.; Loader, J.; Leung, D.Y.; Larsen, G.; Gelfand, E. W. Nebulized But Not Parenteral IFN-Gamma Decreases Ige Production and Normalizes Airways Function in A Murine Model of Allergen Sensitization. J. Immunol. 1994, 152, 2546-2554.
30. Debs, R. J.; Fuchs, H. J.; Philip, R.; Montgomery, A. B.; Brunette, E. N.; Liggitt, D.; Patton, J. S.; Shellito, J. E. Lung-Specific Delivery of Cytokines Induces Sustained Pulmonary and Systemic Immunomodulation in Rats. J. Immunol. 1988, 140, 3482-3488.
31. Kessler, R.; Dumont, S.; Bartholeyns, J.; Weitzenblum, E.; Poindron, P. Antitumoral Potential of Aerosolized Interferon-Gamma in Mice Bearing Lung Metastases. Am. J. Respir. Cell Mol. Biol. 1994, 10, 202-206.
32. Giosue, S.; Casarini, M.; Ameglio, F.; Alemanno, L.; Saltini, C.; Bisetti, A. Minimal Dose of Aerosolized Interferon-Alpha in Human Subjects: Biological Consequences and Side-Effects. Eur. Respir. J. 1996, 9, 42-46.
33. Jaffe, H. A.; Buhl, R.; Mastrangeli, A.; Holroyd, K. J.; Saltini, C.; Czerski, D.; Jaffe, H. S.; Kramer, S.; Sherwin, S.; Crystal, R. G. Organ Specific Cytokine Therapy. Local Activation of Mononuclear Phagocytes by Delivery of an Aerosol of Recombinant Interferon-Gamma to the Human Lung. J. Clin. Invest. 1991, 88, 297-302.
34. Martin, R. J.; Boguniewicz, M.; Henson, J. E.; Celniker, A. C.; Williams, M.; Giorno, R. C.; Leung, D. Y. The Effects of Inhaled Interferon Gamma in Normal Human Airways. Am. Rev. Respir. Dis. 1993, 148, 1677-1682.
35. Halme, M.; Maasilta, P.; Repo, H.; Ristola, M.; Taskinen, E.; Mattson, K.; Cantell, K. Inhaled Recombinant Interferon Gamma in Patients with Lung Cancer: Pharmacokinetics and Effects on Chemiluminescence Responses of Alveolar Macrophages and Peripheral Blood Neutrophils and Monocytes. Int. J. Radiat. Oncol. Biol. Phys. 1995, 31, 93-101.
36. Kinnula, V.; Mattson, K.; Cantell, K. Pharmacokinetics and Toxicity of Inhaled Human Interferon-Alpha in Patients with Lung Cancer. J. Interferon Res. 1989, 9, 419-423.
37. Kinnula, V.; Cantell, K.; Mattson, K. Effect of Inhaled Natural Interferon-Alpha on Diffuse Bronchioalveolar Carcinoma. Eur J. Cancer 1990, 26, 740-741.
38. van Zandwijk, N.; Jassem, E.; Dubbelmann, R.; Braat, M. C.; Rumke, P. Aerosol Application of Interferon-Alpha in the Treatment of Bronchioloalveolar Carcinoma. Eur. J. Cancer 1990, 26, 738-740.
39. deMello, D. E.; Lin, Z. Pulmonary Alveolar Proteinosis: A Review. Pediatr. Pathol. Mol. Med. 2001, 20, 413-432.
40. Armitage, J. O. Emerging Applications of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor. Blood 1998, 92, 4491-4508.
41. Dranoff, G.; Jaffee, E.; Lazenby, A.; Golumbek, P.; Levitsky, H.; Brose, K.; Jackson, V.; Hamada, H.; Pardoll, D.; Mulligan, R. C. Vaccination with Irradiated Tumor Cells Engineered to Secrete Murine Granulocyte-Macrophage Colony-Stimulating Factor Stimulates Potent, Specific, and Long-Lasting Anti-Tumor Immunity. Proc. Natl. Acad. Sci. USA 1993, 90, 3539-3543.
42. Disis, M. L.; Bernhard, H.; Shiota, F. M.; Hand, S. L.; Gralow, J. R.; Huseby, E. S.; Gillis, S.; Cheever, M. A. Granulocyte-Macrophage Colony-Stimulating Factor: An Effective Adjuvant for Protein and Peptide-Based Vaccines. Blood 1996, 88, 202-210.
43. Wing, E. J.; Magee, D. M.; Whiteside, T. L.; Kaplan, S. S.; Shadduck, R. K. Recombinant Human Granulocyte/Macrophage Colony-Stimulating Factor Enhances Monocyte Cytotoxicity and Secretion of Tumor Necrosis Factor Alpha and Interferon in Cancer Patients. Blood 1989, 73, 643-646.
44. Masucci, G.; Wersall, P.; Ragnhammar, P.; Mellstedt, H. Granulocyte-Monocyte-Colony-Stimulating Factor Augments The Cytotoxic Capacity of Lymphocytes and Monocytes in Antibody-Dependent Cellular Cytotoxicity. Cancer Immunol. Immunother. 1989, 29, 288-292.
45. Baxevanis, C. N.; Dedoussis, G. V.; Papadopoulos, N. G.; Missitzis, I.; Beroukas, C.; Stathopoulos, G. P.; Papamichail, M. Enhanced Human Lymphokine-Activated Killer Cell Function After Brief Exposure to Granulocyte-Macrophage-Colony Stimulating Factor. Cancer 1995, 76, 1253-1260.
46. Kumar, R.; Yoneda, J.; Fidler, I. J.; Dong, Z. GM-CSF-Transduced B16 Melanoma Cells are Highly Susceptible to Lysis by Normal Murine Macrophages and Poorly Tumorigenic in Immune-Compromised Mice. J. Leukoc. Biol. 1999, 65, 102-108.
47. Chachoua, A.; Oratz, R.; Hoogmoed, R.; Caron, D.; Peace, D.; Liebes, L.; Blum, R. H.; Vilcek, J. Monocyte Activation Following Systemic Administration of Granulocyte-Macrophage Colony-Stimulating Factor. J. Immunother. Emphasis Tumor Immunol. 1994, 15, 217-224.
48. Spitler, L. E.; Grossbard, M. L.; Ernstoff, M. S.; Silver, G.; Jacobs, M.; Hayes, F. A.; Soong, S. J. Adjuvant Therapy of Stage III and IV Malignant Melanoma Using Granulocyte-Macrophage Colony-Stimulating Factor. J. Clin. Oncol. 2000, 18, 1614-1621.
49. Rose, R. M.; Kobzik, L.; Dushay, K.; Wolfthal, S.; Hondalus, M.; Metzger, M.; Stoudemire, J.; Brain, J. D.; Garnick, M.; O'Donnell, C. The Effect of Aerosolized Recombinant Human Granulocyte Macrophage Colony-Stimulating Factor on Lung Leukocytes in Nonhuman Primates. Am. Rev. Respir. Dis. 1992, 146, 1279-1286.
50. O'Riordan, T. G.; Duncan, S. R.; Burckart, G. J.; Griffith, B. P.; C.; Smaldone, G. Production of An Aerosol of Cycosporin As A Prelude to Clincal Studies. J. Aerosol. Med. 1992, 5, 171-177.
51. Anderson, P. M. Delivery Systems For Immunomodulatory Proteins and Peptides. Biodrugs 1997, 1, 51-65.
52. Ten, R. M.; Anderson, P. M.; Zein, N. N.; Temesgen, Z.; Clawson, M. L.; Weiss, W. Interleukin-2 Liposomes For Primary Immune Deficiency Using The Aerosol Route. Int. Immunopharmacol. 2002, 2, 333-344.
53. Niven, R. W.; Schreier, H. Nebulization of Liposomes. I. Effects of Lipid Composition. Pharm. Res. 1990, 7, 1127-1133.
54. Heyes, J.; J, C.E. Aerosol Chemotherapy of Lung Neoplasia. Nature 1974, 247, 485-487.
55. Gautam, A.; Densmore, C. L.; Waldrep, J.C. Inhibition of Experimental Lung Metastasis by Aerosol Delivery of PEI-P53 Complexes. Mol. Ther. 2000, 2, 318-323.
56. Tatsumura, T.; Yamamoto, K.; Murakami, A.; Tsuda, M.; Sugiyama, S. New Chemotherapeutic Method For The Treatment of Tracheal and Bronchial Cancers - Nebulization Chemotherapy. Gan No Rinsho 1983, 29, 765-770.
57. Tatsumura, T.; Koyama, S.; Tsujimoto, M.; Kitagawa, M.; Kagamimori, S. Further Study of Nebulisation Chemotherapy, A New Chemotherapeutic Method in The Treatment of Lung Carcinomas: Fundamental and Clinical. Br. J. Cancer 1993, 68, 1146-1149.
58. Hershey, A.E.; Kurzman, I. D.; Forrest, L. J.; Bohling, C. A.; Stonerook, M.; Placke, M. E.; Imondi, A.R.; Vail, D. M. Inhalation Chemotherapy For Macroscopic Primary Or Metastatic Lung Tumors: Proof of Principle Using Dogs with Spontaneously Occurring Tumors As A Model. Clin. Cancer Res. 1999, 5, 2653-2659.
59. Knight, V.; Koshkina, N. V.; Waldrep, J. C.; Giovanella, B. C.; Gilbert, B. E. Anticancer Effect of 9-Nitrocamptothecin Liposome Aerosol on Human Cancer Xenografts in Nude Mice. Cancer Chemother. Pharmacol. 1999, 44, 177-186.
60. Koshkina, N. V.; Kleinerman, E. S.; Waidrep, C.; Jia, S. F.; Worth, L. L.; Gilbert, B. E.; Knight, V. 9-Nitrocamptothecin Liposome Aerosol Treatment of Melanoma and Osteosarcoma Lung Metastases in Mice. Clin. Cancer Res. 2000, 6, 2876-2880.
61. Verschraegen, C. F.; Gilbert, B. E.; Huaringa, A. J.; Newman, R.; Harris, N.; Leyva, F. J.; Keus, L.; Campbell, K.; Nelson-Taylor, T.; Knight, V. Feasibility, Phase I, and Pharmacological Study of Aerosolized Liposomal 9-Nitro-20(S)-Camptothecin in Patients with Advanced Malignancies in the Lungs. Ann. N Y Acad. Sci. 2000, 922, 352-354.
62. Wattenberg, L. W.; Wiedmann, T. S.; Estensen, R. D.; Zimmerman, C. L.; Steele, V. E.; Kelloff, G. J. Chemoprevention of Pulmonary Carcinogenesis by Aerosolized Budesonide in Female A/J Mice. Cancer Res. 1997, 57, 5489-5492.
63. Brooks, A. D.; Tong, W.; Benedetti, F.; Kaneda, Y.; Miller, V.; Warrell, R. P.; Jr. Inhaled Aerosolization of All-Trans-Retinoic Acid for Targeted Pulmonary Delivery. Cancer Chemother. Pharmacol. 2000, 46, 313-318.